- Trial phase
- Phase 2
- Time to market
- SLS009 is in Phase 2 testing and has not yet entered a pivotal/registrational trial. If the first-line AML data is positive and the FDA agrees on a registration pathway, a potential NDA filing is likely several years away. The drug could also benefit from Fast Track designation, which enables rolling review and priority review if criteria are met.
- Why 6/10
- A dated binary catalyst exists: topline data from the Phase 2 first-line AML trial (80 patients) is expected in Q4 2026, within ~2 months. However, SLS009 is not the company's sole value driver; the Phase 3 REGAL trial of galinpepimut-S (GPS) just reached its final analysis trigger and represents a separate major catalyst. The score of 6 reflects a near-term pivotal readout on a significant but not lead asset at a company with multiple programs.
The next hard catalyst for SLS009 is the Phase 2 first-line AML topline data readout expected in Q4 2026 (within approximately 2 months). Positive results could validate SLS009's potential as a backbone AML therapy and significantly boost SLS shares, while negative or mixed data would weigh on the stock. Note that the company's Phase 3 REGAL trial for GPS also just reached its 80th event today, creating a dense catalyst cluster for SLS in the near term.
Price Chart
Executive Summary
SLS009 (tambiciclib) is a highly selective CDK9 inhibitor being developed by SELLAS Life Sciences Group (NASDAQ: SLS) for acute myeloid leukemia and potentially other cancers. A Phase 2 trial in relapsed/refractory AML met all primary endpoints in July 2025 with a 44-46% overall response rate and median overall survival of 8.9 months, well above historical benchmarks. The company is now running a randomized Phase 2 trial in newly diagnosed first-line AML (80 patients, 28 enrolled as of mid-2026), with topline data expected in Q4 2026 -- the next major catalyst. SLS009 holds FDA Fast Track, Orphan Drug, and two Rare Pediatric Disease Designations. SELLAS has a strong cash position ($138.3M) but no approved products, and both SLS009 and the Phase 3 GPS program (which just triggered final analysis) represent critical value drivers in the near term.
How It Works
SLS009 is a highly selective inhibitor of CDK9, an enzyme that acts as a master switch for gene transcription in cells. Many cancer cells, particularly in acute myeloid leukemia (AML), depend on short-lived proteins like MCL-1 and MYC to survive. By blocking CDK9, SLS009 shuts down production of these proteins, causing cancer cells to die while largely sparing healthy cells. It is designed to overcome resistance to venetoclax, a standard AML drug that becomes less effective when cancer cells increase MCL-1 production.
Trial Status
A Phase 2 trial in relapsed/refractory AML completed and met all primary endpoints (July 2025). A separate randomized Phase 2 trial in newly diagnosed first-line AML (NCT04588922) began enrollment in March 2026, with 28 of 80 patients enrolled as of Q2 2026. Preclinical studies in pancreatic cancer are also underway.
The Two-Sided Case
Upcoming Catalysts
- Phase 2 first-line AML topline data readout expected in Q4 2026 (within ~2 months)
- Q3 2026 earnings report scheduled November 10, 2026
- Potential clinical development updates for SLS009 in pancreatic cancer following September 2026 preclinical AACR data
- Any FDA regulatory milestone (e.g., meeting to discuss Phase 2 data and registrational path)
Source Filing
The SecBot filing or press-release report that triggered this drug report:
SELLAS Life Sciences Group, Inc. Press Release SLS ·Originating report